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ABSTRACT
DNA gyrase is a DNA topoisomerase indispensable
forcellularfunctionsinbacteria.Wedescribeanovel,
hitherto unknown, mechanism of specific inhibition
of Mycobacterium smegmatis and Mycobacterium
tuberculosis DNA gyrase by a monoclonal antibody
(mAb). Binding of the mAb did not affect either GyrA–
GyrB or gyrase–DNA interactions. More importantly,
the ternary complex of gyrase–DNA–mAb retained
theATPaseactivityoftheenzymeandwascompetent
tocatalyseDNAcleavage–religationreactions,imply-
ing a new mode of action different from other classes
of gyrase inhibitors. DNA gyrase purified from
fluoroquinolone-resistant strains of M.tuberculosis
and M.smegmatis were inhibited by the mAb. The
absence of cross-resistance of the drug-resistant
enzymes from two different sources to the antibody-
mediatedinhibitioncorroboratesthenewmechanism
of inhibition. We suggest that binding of the mAb in
the proximity of the primary dimer interface region of
GyrAintheheterotetramericenzymeappearstoblock
the release of the transported segment after strand
passage, leading to enzyme inhibition. The specific
inhibition of mycobacterial DNA gyrase with the mAb
opens up new avenues for designing novel lead
molecules for drug discovery and for probing gyrase
mechanism.
INTRODUCTION
DNA topoisomerases are a group of enzymes that catalyse
interconversions of different topological forms of DNA (1).
DNA gyrase is a bacterial type II topoisomerase, which is able
to supercoil DNA, a property not shared by other topoisome-
rases (1); the enzyme has now also been found in plants (2).
The mechanism of DNA supercoiling catalysed by gyrase
involves a series of coordinated steps. The tetrameric holoen-
zyme (A2B2), formed by the association of two GyrA and
GyrB subunits, binds duplex DNA to form a wrapped com-
plex, in which one segment of DNA (the transported or ‘T’
segment) lies over another (the gate or ‘G’ segment) (3). The
enzyme carries out transesteriﬁcation reactions leading to
a double-strand break in the G segment and simultaneous
covalent attachment of the protein to the 50 end of the cleaved
duplex DNA. Following ATP binding, conformational
changes in the enzyme pull the two ends of the cleaved G
segment apart to open up a channel, allowing the T segment to
pass into the enzyme. The T segment exits through the bottom
gate of the enzyme, formed by the GyrA dimer, and hydrolysis
of ATP sets up the initiation of the next supercoiling cycle.
The supercoiling reaction of DNA gyrase involves a series
of complicated steps, which provide multiple opportunities to
develop inhibitors. A number of inhibitors of diverse classes
have been characterized (4); quinolones and coumarins are the
most extensively studied. The quinolones are synthetic com-
pounds, which interfere with the processes of rejoining the
double-strand breaks in DNA. Newer quinolones, especially
ﬂuoroquinolones, have found wide applications clinically for a
variety of bacterial infections (5). The coumarins are naturally
occurring antibiotics, which inhibit the ATPase activity of
gyrase (6). Cyclothialidines, a class of cyclic peptides, inhibit
gyrase activity in a manner analogous to that of coumarins. In
addition, two proteinaceous poisons, microcin B17 and CcdB,
inhibit Escherichia coli gyrase in a manner similar to quino-
lones (4). More recently, a chromosomally encoded protein-
aceous inhibitor of gyrase, GyrI, has been characterized (7,8).
Most of these inhibitors fall into two groups based on their
site of action and mechanism of inhibition: inhibitors such
as ﬂuoroquinolones, CcdB and microcin B17 affect the
cleavage–religation step, while coumarins and cyclothial-
idines prevent ATP hydrolysis (4).
One-third of the global population is infected with tuber-
culosis with 6 million new cases reported each year; 20% of
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doi:10.1093/nar/gki622adult deaths and 6% of infant deaths are attributable to
tuberculosis (9). Thus, Mycobacterium tuberculosis is the
largest single infectious cause of mortality worldwide, killing
 2 million people annually (10). The synergy between
tuberculosis and the AIDS epidemic (11), and the rapid rise
in multidrug-resistant clinical isolates of M.tuberculosis have
only reafﬁrmed tuberculosis as a major public health threat.
Studies on mycobacterial DNA gyrase and comparison
of its properties with the E.coli enzyme have revealed
many differences, which can potentially be exploited for
tuberculosis therapy. For example, unlike the E.coli enzyme,
Mycobacterium smegmatis gyrase is refractory to the plasmid-
borne proteinaceous inhibitors CcdB and microcin B17,
and exhibits reduced susceptibility to ﬂuoroquinolones
(12,13). Furthermore, M.smegmatis gyrase is more active
as a decatenase than its E.coli counterpart. One strategy for
the development of inhibitors of mycobacterial gyrase is
to raise antibodies. Polyclonal antibodies raised against
M.tuberculosis GyrA recognize GyrA proteins from other
mycobacteria but not from E.coli (14). Monoclonal antibodies
(mAbs) against the individual subunits of M.smegmatis gyrase
have been raised and characterized (15,16). Two of these
mAbs (C3 and H11) bind within the region between amino
acids 351 and 415 of GyrA and have been shown to inhibit
supercoiling by gyrase. A third antibody (E9) bound else-
where and did not affect gyrase activity (15). In this paper,
we have further investigated the mechanism of inhibition by
one particular antibody, mAb:C3, and show that it inhibits
the enzyme by a completely novel mechanism, which could
be exploited to develop new agents for tuberculosis therapy.
MATERIALS AND METHODS
Bacterial strains and plasmids
M.smegmatismc
2155andciproﬂoxacin-resistantM.smegmatis
strains (17) were obtained from P. K. Chakraborti (Institute
of Microbial Technology, Chandigarh, India). M.smegmatis
cultures was grown in modiﬁed Youmans and Karlson’s
medium with 0.2% Tween-80 (YK medium) at 37 C (18),
and quinolone-resistant M.smegmatis was grown in YK
medium containing 32 mg/ml ciproﬂoxacin. An oﬂoxacin-
resistant M.tuberculosis clinical isolate was grown in Lowen-
stein Jensen medium at 37 C. Plasmid pJW312-SalI used in
the puriﬁcation of E.coli topoisomerase I was obtained from
J. C. Wang (19).
Purification of DNA gyrase
M.smegmatis and M.tuberculosis DNA gyrase holoenzymes
were puriﬁed by novobiocin–Sepharose column as described
by Manjunatha et al. (16). Individual mycobacterial gyrase
subunits were puriﬁed by immunoafﬁnity column chromato-
graphy (13). Fractions containing apparently homogeneous
preparations as judged by SDS–PAGE were used for the
experiments.
Immunoprecipitations, SDS–PAGE and
western blotting
Immunoprecipitations were performed with mycobacterial
gyrase (2 mg) with 15 mg/ml of mAb:C3, mAb:E9 or control
mouse IgG in potassium glutamate buffer as described
previously (16). The samples were analysed by 8% SDS–
PAGE and western blotting with GyrA- (1:20 000) and
GyrB- (1:10 000) speciﬁc polyclonal antibodies. For immuno-
precipitation of covalently closed circular DNA, the linearized
pUC18 (BamHI) was end ﬁlled using labelled dNTPs and
Klenow fragment of DNA polymerase I, followed by ligation
using T4 DNA ligase. DNA gyrase was incubated with various
concentrations of mAb before or after the addition of labelled
DNA at 4 C for 1 h, followed by immunoprecipitation. The
radioactive counts in the pellet and supernatant fractions were
measured.
DNA supercoiling, relaxation and
decatenation reactions
The supercoiling reactions were carried out as described pre-
viously (15). The IC50 was deﬁned as the concentration of the
inhibitor that reduced the enzymatic activity observed with
inhibitor-free controls by 50%. Relaxation and decatenation
reactions were carried out as described previously (13). In
relaxation assays, the enzyme was pre-incubated with
200 nM of mAb at 4 C for 15 min. Decatenation reactions
were carried out in the presence of 500 ng of kDNA from
Leishmania donovani (gift from H. K. Majumder) using 2 U
of M.smegmatis enzyme along with 10 mg/ml ciproﬂoxacin,
20 mg/ml novobiocin, 20 mg/ml each of mAb:C3 and mAb:E9.
Electrophoretic mobility shift assay (EMSA)
EMSAs were carried out using a radiolabelled 240 bp DNA
fragment encompassing the strong gyrase site from pBR322
(20). Labelled DNA (0.1 nM) was incubated with 5 nM myco-
bacterial gyrase in supercoiling buffer for 30 min at 4 C. For
supershift assays, 5 nM of antibody was added either to the
enzyme or to the DNA–enzyme complex. Unlabelled 240 bp
DNA (5 and 10 times excess) was used in competition reac-
tions. The samples were electrophoresed on a 3.5% native
polyacrylamide gel at 4 C in 0.5· TBE buffer containing
10 mM MgCl2.
ATPase reaction
ATPase assays were performed as described previously (21)
with 10 U of puriﬁed M.smegmatis DNA gyrase with or with-
out pre-incubation of 120 mg/ml mAb or control mouse IgG
or 20 mg/ml novobiocin at 4 C for 30 min.
Cleavage and religation assays
Cleavage reactions (12.5 ml) were carried out in supercoil-
ing buffer with linear radiolabelled 240 bp DNA fragment
or negatively supercoiled DNA with varying concentrations
of DNA gyrase in the presence of 30 mgm l
 1 ciproﬂoxacin as
described previously (21). The samples were analysed on a 6%
denaturing polyacrylamide gel or 1.2% agarose gel. For religa-
tion assays, the quinolone-induced cleavage reaction (after
15 min) was further incubated with 10 mM EDTA for 15 min
at 37 C, followed by denaturation and proteinase K treatment.
Surface plasmon resonance
The mAb:GyrA:GyrB interaction was assessed on rabbit anti-
mouse Fc antibody immobilized on a CM5 surface in a buffer
containing 35 mM Tris–HCl (pH 7.6), 100 mM potassium
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MsGyrA:C3 IgG was passed across the surface, followed by
100 nM of puriﬁed GyrA. Subsequently, GyrB (100 nM) was
allowed to interact and the GyrA–GyrB interaction was spe-
ciﬁcally disrupted in running buffer with 500 mM NaCl (16);
10 mM NaOH was used for surface regeneration. For meas-
uring the mAb–GyrA binding afﬁnities, the M.smegmatis
GyrA was immobilized on the CM5 sensor chip and all meas-
urements were carried out as described previously (16).
RESULTS
A GyrA-specific mAb inhibits DNA supercoiling,
relaxation and decatenation by mycobacterial gyrase
In previous work, we showed that mAb:C3 (IgG1), and its
corresponding Fab fragment, inhibited M.smegmatis DNA
gyrase supercoiling activity (15), whereas mAb:E9 (IgG1)
showed no effect on this reaction; neither antibody affected
the supercoiling reaction of the E.coli enzyme. In the presence
of stoichiometric amounts of mAb:C3 to M.smegmatis GyrA,
complete inhibition of DNA supercoiling was observed (data
not shown). In Figure 1A, we summarize the effects of C3 and
E9 on the supercoiling reaction of M.smegmatis gyrase. We
note a small increase in negative supercoiling in the presence
of gyrase and C3, suggesting that limited strand passage may
be possible in the presence of this antibody (see below).
The binding of mAb:C3 to DNA gyrase also inhibited the
ATP-independent relaxation of negatively supercoiled DNA
(Figure 1B); again no effect was seen with E9. Similar results
were observed with Fab fragments (data not shown). Apart
from intra-molecular strand passage leading to supercoiling
or relaxation of DNA, gyrase also catalyses inter-molecular
strand passage during the decatenation reaction (22); myco-
bacterial gyrase is an efﬁcient decatenase (13). Therefore,
the effect of mAb on the decatenation of catenated kineto-
plast DNA was studied. As shown in Figure 1C, mAb:C3 also
inhibited the decatenation activity of kinetoplast DNA to
minicircles.
Effect of mAb on subunit assembly
Using surface plasmon resonance, we found the afﬁnity of
interaction (KD) of mAb:C3, and its Fab fragment, with
M.smegmatis GyrA to be 2.2 · 10
 10 M and 1.7 · 10
 10 M,
respectively (data not shown), implying that the speciﬁc
inhibition seen above is a consequence of a high-afﬁnity
interaction of mAb with gyrase. To address whether this
high afﬁnity binding of mAb:C3 to GyrA disrupts the
GyrA dimer or GyrA–GyrB interactions, immunoprecipitation
experiments were carried out. We found that mAb:C3
co-immunoprecipitated GyrB along with GyrA (Figure 2A),
suggesting that the binding of the mAb does not disrupt
subunit interaction. In contrast, another GyrA-speciﬁc anti-
body, MsGyrA:E9, which binds to different epitope masked
in the holoenzyme, fails to immunoprecipitate the gyrase
subunits (Figure 2A, lane 6) as observed previously (15).
Surface plasmon resonance studies showed that when
mAb:C3 was bound to the chip, GyrA could be bound and
GyrB could then bind to the GyrA, conﬁrming that the
mAb-bound GyrA subunit interacts with GyrB (Figure 2B).
Figure 1. Inhibition of different enzymatic activities of DNA gyrase by
mAb:C3. (A) Supercoiling: one unit of M.smegmatis DNA gyrase was pre-
incubatedwithantibody(IgGorFabasindicated),asdescribedinMaterialsand
Methods, and supercoiling assays were carried out using relaxed pUC18 as
substrate.Sampleswereanalysedon1.2%agarosegels;RandSarerelaxedand
negativelysupercoiledpUC18DNA,respectively. (B) ATP-independent DNA
relaxation: mAb was pre-incubated with gyrase and relaxation assays were
carriedoutusingsupercoiledpUC18DNAassubstrate.Sampleswereanalysed
as described for the supercoiling assay. (C) Decatenation activity: reactions
were carried out in the presence of kDNA (lane 1) with M.smegmatis enzyme
(lane 2) along with ciprofloxacin (Q, lane 3), novobiocin (N, lane 4), mAb:C3
and E9 (C3 and E9, lanes 5 and 6, respectively). kN, kDNA network; BN,
broken network.
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protein interactions in gyrase.
Effect on DNA binding
EMSA and immunoprecipitation experiments were employed
to evaluate the effect of mAb:C3 on gyrase–DNA interaction.
Using EMSA, we found that mAb:C3 caused further retarda-
tion of the gyrase–DNA complex in a polyacrylamide gel,
without release of free DNA (Figure 3A). A similar supershif-
ted complex was also observed when Fab fragments were used
in the assay instead of intact mAb (data not shown). However,
control antibody showed no effect on gyrase–DNA interaction
(Figure 3A). Because covalently closed circular DNA is the
substrate for DNA supercoiling by gyrase, an immunoprecip-
itation reaction with such a substrate, mAb and gyrase was
carried out. Formation of a gyrase–mAb–DNA ternary com-
plex (Figure 3B) suggests that mAb:C3 neither inhibits gyrase
subunit interaction nor inhibits DNA binding.
Binding of mAb does not block quinolone-stabilized
DNA cleavage
In the preceding sections, we have shown that mAb:C3 does
not affect subunit interaction or DNA binding by DNA gyrase.
Figure 2. Effect of mAb:C3 on DNA gyrase subunit interaction. (A) Immu-
noprecipitation assay: Gyrase was immunoprecipitated with mAb:C3 or
mAb:E9 or control mouse IgG. Immunocomplexes were recovered using
protein G agarose. Both pellet (P) and supernatant (S) protein fractions were
analysed by SDS–PAGE followed by western blotting with GyrA- or GyrB-
specific polyclonal antibodies. (B) Surface plasmon resonance: a sensogram
showing the interaction of gyrase subunits on rabbit a-mouse (RAM) Fc
immobilized CM5 surface through mAb:C3. The various steps of interaction
are shown schematically along with the bound response units. I: binding of C3
to a-mouse Fc; II: binding of GyrA to C3; III: binding of GyrB to GyrA;
IV: dissociation of GyrB after salt wash.
Figure 3. mAb binding to the gyrase–DNA complex. (A) EMSA with 240 bp
labelled DNA fragment (lane 1) was carried out with gyrase (lane 2) incubated
with control mouse immunoglobulin (NM Ig, lane 3) or gyrase with mAb:C3
(lane 4). The samples were electrophoresed on a 3.5% native polyacrylamide
gel and autoradiographed. (B) Immunoprecipitation of covalently closed cir-
cular DNA. The enzyme was incubated with various concentrations of mAb
(mAb:C3ormAb:E9),followedbytheadditionofradiolabelledrelaxedpUC18
DNAandimmunoprecipitationwascarriedout.TheDNApresentintheGyrA–
antibody complex (pellet) and the unbound (supernatant) were measured using
liquid scintillation counter.
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such that the addition of SDS to the ternary complex of
gyrase–DNA–quinolone results in DNA cleavage and reveals
covalent attachment of the enzyme to the DNA (23,24).
The ciproﬂoxacin-stabilized DNA cleavage reaction was
used to assess the ability of the mAb to inhibit cleavage of
the G segment. Pre-incubation of gyrase with inhibitory
concentrations of mAb:C3 did not abolish quinolone-
stabilized cleavage of either linear (Figure 4A) or negatively
supercoiled DNA (Figure 4C). The amount of cleavable
complex with the enzyme remained unaltered in the presence
of saturating amounts of mAb (75 mg/ml) (Figure 4A and B);
3 mg/ml mAb is sufﬁcient to completely inhibit super-
coiling with 1 U of the enzyme (15). The DNA cleavage
pattern remained unaltered in the presence or absence of
mAb (Figure 4A). Furthermore, the data presented in
Figure 4C, lane 9, indicate that mAb by itself did not induce
or stimulate DNA cleavage by gyrase. Thus, the mechanism
of inhibition of DNA gyrase by mAb is distinct from that of
quinolones.
Limited proteolysis experiments (25) have shown that
the formation of the gyrase–DNA–quinolone ternary complex
results in large conformational changes in the enzyme,
raising the possibility that mAb:C3 may fail to interact with
quinolone-stabilized DNA gyrase. In order to address this
possibility we examined whether mAb:C3 could still interact
with a quinolone-stabilized gyrase–DNA complex using
EMSA. While unlabelled DNA competed out non-covalent
gyrase–DNA complexes (Figure 4D, lanes 3 and 4), the
quinolone-stabilized complex could not be competed out,
even with a large excess of DNA, indicating the formation
of a stable, covalent cleavage complex (Figure 4D, lane 5).
The appearance of a supershifted complex with the addition of
the mAb (Figure 4D, lane 6) indicates that quinolone-induced
conformational changes in the enzyme–DNA complex did
not prevent mAb:C3 interaction with the enzyme.
The above results essentially demonstrate that G-segment
binding and its subsequent cleavage by DNA gyrase were not
inhibited by the mAb. DNA gyrase catalyses religation of
the cleaved G segment after passage of the T segment through
theDNA gate.Thereligationactivityofgyrasecanbeassessed
by adding EDTA to the gyrase–DNA–ciproﬂoxacin ternary
complex (23,24,26). The binding of antibody to the gyrase–
DNA–ciproﬂoxacin ternary complex had no effect on the
reversibility of DNA cleavage (Figure 4E). EDTA by itself
had no effect on GyrA–mAb interactions (data not shown).
These results suggest that the mAb:C3 binding to gyrase does
not affect the cleavage or religation steps of the supercoiling
reaction.
Effect of mAb on ATPase activity of gyrase
ATP hydrolysis is essential for catalytic supercoiling by
DNA gyrase. We found that mAb:C3 did not abolish the
ATP hydrolysis activity of gyrase even when saturating
amounts of mAb were used (Figure 5), whereas ATPase
activity was completely inhibited by 5 mg/ml novobiocin.
The mechanism of inhibition of gyrase by mAb:C3 is thus
distinct from that of coumarins. The partial inhibition of the
ATPase activity (Figure 5) may be signiﬁcant and will be
discussed below.
The effect of mAb:C3 on T-segment passage
Although the results in Figure 1 suggested that mAb:C3 inhib-
its supercoiling by DNA gyrase, there was evidence of low-
level activity in the presence of the antibody. To explore this
further, and address the effect of mAb on the strand-passage
event, supercoiling assays were performed with a range of
gyrase:DNA ratios in the presence of saturating amounts of
mAb:C3. Under these conditions, we see further evidence of
limitedsupercoilinginthepresenceoftheantibody(Figure6A,
lanes 4–6), indicating that some strand passage of the T seg-
ment through the DNA–protein gate is possible under these
conditions. At the higher enzyme concentrations, under these
reaction conditions, we noted a slower moving species that
was resistant to proteinase K digestion (Figure 6A, lanes 4–6).
EM analysis of this species suggested that it is catenated DNA
(data not shown). The appearance of catenated DNA, only at
higher enzyme–DNA ratios, indicates that its formation might
be a non-catalytic function of mAb-bound gyrase. In addition,
the mAb-mediated catenane formation did not increase with
time, suggesting that the reaction did not involve enzyme
turnover. The formation of DNA catenanes is speciﬁc to
mAb:C3 (both IgG as well as Fab) interaction with mycobac-
terial gyrase, as another mAb raised against mycobacterial
gyrase, E9, had no effect (Figure 6A, lane 7); mAb:C3 did
not affect E.coli gyrase activity (data not shown).
In the presence of the non-hydrolysable ATP analogue
ADPNP (50-adenylyl b,g-imidodiphosphate), DNA gyrase
can catalyse limited supercoiling (27). This result is consistent
with nucleotide binding enabling one round of strand passage
(28,29). In order to establish whether gyrase can catalyse
limited strand passage in the presence of mAb:C3, we have
examined the ADPNP reaction in the presence of this antibody
(Figure 6B). The appearance of additional topoisomers in the
presence of both ADPNP and mAb:C3 demonstrates that the
mAb may permit a single-strand passage event (Figure 6B,
lane 5). Supercoiling reactions in the presence of ADPNP
alone showed a similar pattern (data not shown). These results
together indicate that binding of the antibody allows limited
strand-passage reaction.
Inhibition of quinolone-resistant DNA gyrase from
M.smegmatis and M.tuberculosis
Since the inhibition of mycobacterial DNA gyrase super-
coiling activity by mAb:C3 is by a mechanism very different
from known modes of inhibition, the enzyme from quinolone-
resistant strains should be susceptible to antibody-mediated
inhibition. DNA gyrase from the ciproﬂoxacin-resistant
M.smegmatis mc
2155 strain (MIC50 64 mg/ml) was puriﬁed
and used to test this prediction. The enzyme from the
quinolone-sensitive strain showed an IC50 of  5 mg/ml for
ciproﬂoxacin, whereas the enzyme from the resistant strain
showed no inhibition even at 200 mg/ml (Figure 7A). DNA
supercoilingactivitywasinhibitedat3and6mg/mlofmAb:C3
for quinolone-sensitive and quinolone-resistant enzymes,
respectively (Figure 7B), i.e. there is no apparent resistance
to the antibody. DNA gyrase from the oﬂoxacin-resistant,
highly virulent clinical isolate of M.tuberculosis (ICC-222)
was also assayed for the effect of mAb. DNA gyrase from
both the species of mycobacteria are similar in their size,
Nucleic Acids Research, 2005, Vol. 33, No. 10 3089Figure 4. Effect of mAb on quinolone-stabilized cleavage and religation reactions. Cleavage reactions using a 240 bp labelled fragment of DNA (A and E) or
negatively supercoiled pBR322 (C) as substrate in the presence of varying amounts of enzyme and different mAbs as indicated. (B) Quantitative representation of
cleavedproductsof(A). (D) EMSAusing240 bplabelledfragmentofDNAin thepresenceof5·or10· competitor unlabelledDNA andciprofloxacin. (E) EDTA-
induced religation reaction. A gyrase–CFX–DNA cleavage reaction (lane 2) was further incubated without (lanes 3 and 4) or with EDTA treatment (lanes 5 and 6).
In lanes 4 and 6, the enzyme was pre-incubated with MsGyrA:C3.
3090 Nucleic Acids Research, 2005, Vol. 33, No. 10properties and antigenic cross reactivity (14–16). The puriﬁed
enzyme has an IC50 of  10 mg/ml for ciproﬂoxacin, whereas
the mAb:C3 inhibited the supercoiling activity at 3.0 mg/ml,
the same concentration required for the inhibition of
M.smegmatis enzyme (Figure 7C). The absence of cross-
resistance conﬁrms the mode of action of mAb to be distinct
to that of quinolones.
DISCUSSION
Most DNA gyrase inhibitors target only two different steps
amongst many others during the supercoiling reaction. The
high afﬁnity, stoichiometric binding of mAb:C3 to GyrA sug-
gests that its mode of inhibition is distinct. Binding of the mAb
neither affected subunit interactions nor affected enzyme–
DNA interactions, and a gyrase–holoenzyme DNA–mAb tern-
ary complex is readily formed. The ternary complex retained
DNA cleavage and religation activities. The conformational
changes induced in the quinolone-stabilized cleavable com-
plex (25) did not affect mAb binding. The antibody by itself
did not arrest the reaction before the second transesteriﬁcation,
implying that the mode of action of mAb is distinct from
that of quinolones. DNA gyrases from a quinolone-resistant
M.smegmatis and M.tuberculosis were sensitive to mAb
action, conﬁrming the distinct mode of inhibition.
Furthermore, unlike coumarins, binding of mAb:C3 to
mycobacterial gyrase did not abolish ATP hydrolysis by the
enzyme. Cleavage of the G segment and capture of the T
segment by the ATP-operated clamp is required to stimulate
the ATPase activity of DNA gyrase (30,31). The retention of
ATPase activity in the mAb–gyrase complex indicates that the
presentation of the T segment to the ATP-operated clamp is
not perturbed. The partial inhibition of the ATPase activity in
the presence of C3 (Figure 5) may suggest some perturbation
of the strand-passage reaction in the presence of the antibody
(see below).
Aconformation-dependentepitope,comprisingamino acids
351 and 415 of GyrA, is recognized by the mAb (15).
Sequence alignment with the E.coli GyrA subunit revealed
that this stretch corresponds to amino acid residues between
340 and 402 of E.coli GyrA. These residues form a long
helix (a14), positioned in the proximity of the primary
dimer interface region. The structure is present in yeast topoi-
somerase II (32) and seems to be conserved in all other type II
topoisomerases. From thesequencecomparison andsecondary
structure prediction, the mAb interacting domain of myco-
bacterial gyrase appears to form a similar structure. The con-
served long alpha helix is an integral part in the formation of
the second gate for the exit of the T segment during catalysis
(33). The binding of the mAb proximal to the bottom dimer
interface region could effectively block the exit gate.
Figure 5. Effect of mAb on ATP hydrolysis. ATPase assays were carried out
with75nMofM.smegmatisDNAgyraseinthepresenceofsupercoiledpBR322
DNA.Theenzyme(E)waspre-incubatedin thepresenceofmAb:C3(C3 IgG),
controlmouseIgG(NMIgG)ornovobiocin,andATPasereactionswerecarried
out as described previously. The DNA-dependent ATPase rate is shown.
Figure 6. Effect of mAb on the strand-passage reaction. (A) The indicated
amounts of enzyme (1 U = 25 fmol) were pre-incubated with 24 pmol of the
mAb:C3 or mAb:E9 at 4 C for 15 min. An aliquot of 250 fmol of the relaxed
DNA were added to the enzyme–antibody complex in supercoiling buffer and
then incubated for 2 h at 37 C. SDS (0.16%) and proteinase K (90 mg/ml) were
than added and the incubation continued for 30 min at 37 C. Samples were
analysed on a 1.2% agarose gel electrophoresed at 25 V for 30 h. The slow
migratingbandinlanes5and6isthoughttobeacatenatedspecies,asindicated.
(B) Singleroundsupercoiling. The assaysare carriedout as abovewith 15 U of
enzyme(lanes2–5).Lane1,noenzyme;lane5,0.5mMADPNPispresentalong
with mAb:C3.
Nucleic Acids Research, 2005, Vol. 33, No. 10 3091Based on the data in this paper, we propose a model for the
interaction of mAb:C3 with GyrA and how this interaction
inhibits DNA supercoiling (Figure 8). Supercoiling by gyrase
involves wrapping of DNA around the enzyme such that
the T segment lies over the G segment (3). Cleavage of the
G segment allows passage of the T segment through the break
and into the enzyme. The T segment is released by the opening
of the exit gate [primary dimer interface (33)]. The epitope
for mAb:C3 lies near this interface. Binding of the Ab to
this region and blocking of the exit gate could account for
the results we have observed. Such a mode of action would
neither affect protein–protein and protein–DNA interactions
by gyrase nor would it affect DNA cleavage–religation by
the enzyme; in this sense, the action of mAb:C3 resembles
the effect of cross-linking the exit gate of gyrase (34) and yeast
topoisomerase II (35). Blocking of the exit gate would be
expected to inhibit all strand-passage reactions of gyrase, as
we have observed (Figure 1). The evidence of limited super-
coiling (Figures 1A and 6) would be consistent with the mAb
blocking step III of the supercoiling cycle (Figure 8) and just
allowing one cycle of strand passage, again consistent with
what has been observed in cross-linking experiments (34).
DNA-dependent ATP hydrolysis requires binding of both
the G and the T segments to gyrase and would not necessarily
be expected to be affected by the Ab. However, the low-level
inhibition seen (Figure 5) might be a consequence of the
failure of the enzyme to release the T segment; very similar
observations were made with enzyme cross-linked at the exit
gate (34). This proposed mode of inhibition is very different
from that of known antibiotics.
The results highlight the opportunities to exploit DNA
gyrase as a drug target relying on novel strategies. Antibody
mAb:C3 cross-reacts with GyrA from other mycobac-
teria [Mycobacterium bovis, Mycobacterium leprae and
Mycobacterium avium (15)] but not with the E.coli enzyme,
it thus opens up the avenues for strategic design of speciﬁc
lead molecules targeted against mycobacterial infections. This
is in contrast to quinolones, coumarins and cyclothialidines,
which inhibit DNA gyrases from many bacterial species. Anti-
gen binding by peptide sequences from selected complement-
arity determining regions of mAbs have been demonstrated to
have speciﬁcities similar to those of the original antibody
molecule (36,37). These examples form the basis for the
design of peptides that would speciﬁcally inhibit DNA gyrase
from mycobacteria. The ability of small molecules to select-
ively stabilize a transient dimer interface within a type II DNA
topoisomerase has been demonstrated previously. Classen
et al. (38) showed that ICRF-187 binding to topoisomerase
Figure 7. Inhibition of DNA gyrase from quinolone-resistant mycobacteria. Supercoiling reactions were carried out in the presence of varying concentrationso f
ciprofloxacin(CFX)(A)ormAb:C3(B),withCFX-sensitiveorCFX-resistantenzymes,isolatedfromwild-typeanddrug-resistantM.smegmatis,asindicated.Rand
S are relaxed and negatively supercoiled pUC18 DNA, respectively. (C) Supercoiling reactions carried out with DNA gyrase isolated from an ofloxacin-resistant
M.tuberculosis strain, in the presence of CFX and mAb:C3, as indicated.
3092 Nucleic Acids Research, 2005, Vol. 33, No. 10II stabilizes ATP-bound dimerized state preventing enzyme
turnover. The absence of cross-resistance to ﬂuoroquinolone-
resistant DNA gyrase by the mAb warrants the pursuit of this
strategy further as it could aid in counteracting drug resistance
problems. In addition, these new inhibitors would be invalu-
able tools in elucidating various steps of the supercoiling
reaction, which in turn would facilitate the rational design
of lead molecules.
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